Sanofi Gains FDA Approval for Subcutaneous Isatuximab-irfc Delivered via CirCLIQ On-Body Device

The FDA's 9 July 2026 approval of isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection marks a concrete inflection point for fill-finish teams and QA directors managing drug-device combination products: a high-volume oncology biologic is now commercially approved for delivery via an on-body delivery system (OBDS), the CirCLIQ, alongside a manual syringe-and-infusion-set option at a fixed 1,400 mg subcutaneous dose.

Three multiple myeloma indications are covered under the approval: in combination with pomalidomide and dexamethasone for patients with at least one prior line of therapy including lenalidomide and a proteasome inhibitor; in combination with carfilzomib and dexamethasone for relapsed or refractory disease after one to three prior lines; and in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed patients ineligible for autologous stem cell transplant. The breadth of indications signals sustained commercial volume, which directly shapes batch release planning and device component supply chains.

Efficacy data supporting the subcutaneous route came from three studies. The pivotal IRAKLIA trial (NCT05405166), a 531-patient open-label non-inferiority study, demonstrated overall response rates of 71.1% (subcutaneous) versus 70.5% (intravenous), with a subcutaneous/IV geometric mean ratio for steady-state Ctrough of 1.53 (90% CI: 1.32–1.78), confirming pharmacokinetic non-inferiority. The IZALCO study (NCT05704049, n=74) returned an ORR of 79.7% in relapsed/refractory patients, while the investigator-sponsored IsaSocut study (NCT05889221, n=74) reported a 97.3% ORR in newly diagnosed, transplant-ineligible patients.

For regulatory affairs leads, the approval carries combination product classification implications. The CirCLIQ OBDS falls under 21 CFR Part 3 combination product jurisdiction, requiring coordinated CDER and CDRH oversight and a device constituent part that must meet its own design controls and biocompatibility standards. Manufacturing teams integrating OBDS assembly into GMP fill-finish workflows will need to reconcile drug product specifications with device performance requirements, including container closure integrity and extractables/leachables profiles aligned with ICH Q3E expectations as guidance matures.

The prescribing information lists warnings for hypersensitivity and administration reactions, neutropenia, infections, secondary primary malignancies, laboratory test interference, and embryo-fetal toxicity. Isatuximab-irfc received orphan drug designation, and the submission used the FDA's voluntary Assessment Aid to facilitate review.

Full prescribing information will be posted to Drugs@FDA; CDMOs and in-house operations teams establishing device-drug co-manufacturing protocols should treat that posting as a baseline document for ongoing process validation planning.

Source: FDA Oncology Center of Excellence via FDA.gov Drugs RSS Feed, 10 July 2026.